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Abstract: The use of probiotics and synbiotics in the prevention and treatment of different disorders
has dramatically increased over the last decade. Both probiotics and synbiotics are well known
ingredients of functional foods and nutraceuticals and may provide beneficial health effects because
they can influence the intestinal microbial ecology and immunity. The present study reviews the
effects of probiotics and synbiotics on obesity, insulin resistance syndrome (IRS), type 2 diabetes
(T2D) and non-alcoholic fatty liver disease (NAFLD) in human randomized clinical trials. Select
probiotics and synbiotics provided beneficial effects in patients with obesity, mainly affecting the
body mass index and fat mass. Some probiotics had beneficial effects on IRS, decreasing the cell
adhesion molecule-1 levels, and the synbiotics decreased the insulin resistance and plasma lipid
levels. Moreover, select probiotics improved the carbohydrate metabolism, fasting blood glucose,
insulin sensitivity and antioxidant status and also reduced metabolic stress in subjects with T2D.
Some probiotics and synbiotics improved the liver and metabolic parameters in patients with NAFLD.
The oral intake of probiotics and synbiotics as co-adjuvants for the prevention and treatment of obesity,
IRS, T2D and NAFLD is partially supported by the data shown in the present review. However,
further studies are required to understand the precise mechanism of how probiotics and synbiotics
affect these metabolic disorders.
Keywords: probiotics; randomized clinical trial; obesity; insulin resistance; metabolic syndrome X;
type 2 diabetes; non-alcoholic fatty liver disease; synbiotics
1. Introduction
The microbiota (the full collection of microbes that naturally exist within a particular biological
niche) has a profound influence on human physiology, affecting metabolism and the immune
system and protecting against pathogens while modulating gastrointestinal (GI) development [1–3].
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Perturbations in the composition of the microbiota may be especially important during early life,
when the immune system is still developing [4].
Obesity is one of the most important public health problems worldwide, affecting both developed
and emerging countries. It is characterized by an abnormal excess of white adipose tissue, which is
a major risk factor for the development of diabetes, cardiovascular disease and cancer [5,6]. Among
the studied potential determinants of obesity, the intestinal microbiota has been proposed to have an
impact on the energy balance in humans [7–11]. Specific bacterial populations, such as Prevotellaceae,
Blautia coccoides, Eubacteria rectale group, Lactobacillus, and Bifidobacterium, have been reported to be
related to obesity. Consequently, it is believed that modulation of the intestinal microbiota toward a
healthier “non-obese” profile might present a promising tool for prevention [12].
Metabolic syndrome is referred to as syndrome X or insulin resistance syndrome (IRS). Currently,
the number of individuals with IRS is increasing worldwide and is primarily composed of those
with abdominal obesity, glucose intolerance, dyslipidemia and high blood pressure. IRS increases
cardiovascular morbidity and mortality as well as overall mortality [13]. Low insulin sensitivity,
particularity in the visceral adipose tissue, leads to increased free fatty acid flux and inhibition of
insulin action in insulin-sensitive tissues. Moreover, IRS is also associated with the development of
diabetes mellitus [13,14].
There are about 382 million people living with diabetes in the world, and the number is expected
to rise to 592 million by 2035 according to the International Diabetes Federation. The pathogenetic
mechanism of type 2 diabetes (T2D) has not yet been completely elucidated. Recent evidence suggests
that the intestinal microbiota composition is associated with the development of T2D [15]. A clear
relationship has been demonstrated between T2D and compositional changes in the gut microbiota,
with a lower relative abundance of Firmicutes and a higher proportion of Bacteroidetes and Proteobacteria
in T2D patients [16,17].
Non-alcoholic fatty liver disease (NAFLD) is the most common type of liver disease worldwide
that affects both adults and children. NAFLD encompasses a broad spectrum of diseases from simple
steatosis at early stages to non-alcoholic steatohepatitis (NASH) and fibrosis, and it eventually may lead
to cirrhosis. NAFLD may be caused mainly by obesity, but it can also be caused by T2D, glucocorticoids,
and small bowel bacterial overgrowth (SIBO) caused by inflammatory bowel disease. Considering
the intimate relationship between the intestine and the liver (called the gut-liver axis), it is becoming
widely accepted that the composition of the gut microbiota is an environmental factor that affects host
metabolism and contributes to the associated pathological conditions, such as obesity [18].
Probiotics are live microorganisms that confer a health benefit on the host when administered
in adequate amounts [19], although dead bacteria and their components can also show probiotic
properties. Bifidobacterium and Lactobacillus strains are the most widely used bacteria exhibiting
probiotic properties and are included in many functional foods and dietary supplements [20]. Major
mechanisms underlying the antagonistic effects of probiotics include improvement of the gut barrier
function, increased competitive adherence to the mucosa and epithelium, gut microbiota modification,
and regulation of the gut associated lymphoid immune system. In this sense, probiotics communicate
with the host through intestinal cell pattern recognition receptors, such as toll-like receptors
and nucleotide-binding oligomerization domain-containing protein-like receptors, which modulate
important key signaling pathways, such as nuclear factor-κB and mitogen-activated protein kinase,
to enhance or suppress activation and influence downstream pathways [21–25].
A prebiotic is a nonviable food component that confers a health benefit on the host associated
with modulation of the microbiota, they may be a fiber, but a fiber is not necessarily a prebiotic. Using
prebiotics and probiotics in combination is often described as synbiotic, only if the net health benefit is
synergistic [26].
Probiotics and synbiotics are consumed in many and diverse forms, such as yogurt and other
fermented milks, cheese and several fermented foods, and also as prevention and treatment for different
GI tract dysfunctions and other diseases like allergy [27]. However, the actual effects of probiotics to
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affect intestinal ecology is still under debate because there are numerous confounding elements, such
as dissimilarities in microbial strains, concentrations of viable cells and product formulations [3,28,29].
Recently, Yoo and Kim (2016) [30] have indicated that probiotics and prebiotics affect
T2D and cardiovascular diseases by changing gut microbiota, regulating insulin signaling,
and lowering cholesterol.
The present review was conducted to investigate the effectiveness of probiotics and synbiotics
in the prevention and treatment of obesity, IRS, T2D and NAFLD in human studies designed as
clinical trials.
2. Results
2.1. Effects of Probiotics and Synbiotics on Obesity
2.1.1. Probiotics
Lactobacillus salivarius Ls-33 was tested in obese adolescents to investigate its impact on
fecal microbiota and anthropometric measures, biomarkers related to inflammation, carbohydrate
and lipid metabolism. The ratios of Bacteroides, Prevotellae, and Porphyromonas group bacteria to
Firmicutes-belonging bacteria, including Clostridium cluster XIV, Blautia coccoides, Eubacterium rectale
group and Roseburia intestinalis, were significantly increased after the administration of L. salivarius
Ls-33. However, the overall cell numbers of fecal bacteria, including the groups above as well
as Clostridium cluster I and cluster IV, Faecalibacterium prausnitzii, Enterobacteriaceae, Enterococcus,
Lactobacillus group and Bifidobacterium spp., were not significantly altered by intervention. Similarly,
the short chain fatty acids (SCFA) remained unaffected [31]. Moreover, Gobel et al., (2012) [32] carried
out an intervention to study the Lactobacillus salivarius Ls-33 effects on some inflammation biomarkers
and several parameters of metabolic syndrome in adolescents with obesity. However, they did not find
changes in those parameters.
The effect of L. gasseri SBT2055 was examined in two studies using a cohort of Japanese
adults with large visceral fat areas (VFA). The participants were randomly assigned to three groups
receiving increasing colony-forming units (CFUs) of L. gasseri SBT2055 for 12 weeks. The results
showed a reduction in body mass index (BMI), waist, abdominal VFA and hip circumferences [33,34].
Additionally, a hypocaloric diet supplemented with a probiotic-enriched cheese containing Lactobacillus
plantarum reduced the BMI, the putrescine content and the intestinal lactobacilli in Russian adults
with obesity and hypertension. Similarly, there was a reduction in the blood pressure (BP), namely a
lower diastolic BP and a tendency toward lower systolic BP at the end of the intervention in the obese
hypertensive patients that received the hypocaloric diet supplemented with the probiotic cheese [35].
The administration of L. acidophilus La5, B. lactis Bb12, and L. casei DN001 was evaluated in
individuals with high BMI who were randomly assigned to three groups depending on particular
intervention diets: one group was established with a regular yogurt with low calorie diet (RLCD),
the second one received a probiotic yogurt with low calorie diet (PLCD) and, the third one received
probiotic yogurt without low calorie diet (PWLCD) for about two months. A reduction in BMI,
fat percentage, and leptin level was observed that was more obvious in groups who received the
weight-loss diet including probiotic yogurt. Additionally, a reduction in the serum levels of CRP was
more evident in the PWLCD group than in the PLCD and RLCD groups after the 8-week intervention.
The expression of the FOXP3, T-bet, GATA3, TNF-α, IFN-γ, TGF-β, and ROR-γt genes in peripheral
blood mononuclear cell (PBMCs) were assessed before and after intervention. In the three groups,
ROR-γt expression was reduced and FOXP3 was increased. The expression of the TNF-α, TGF-β,
and GATA3 genes did not change. Interestingly, T-bet gene expression was down-regulated in the PLCD
and PWLCD groups. However, the IFN-γ expression was down-regulated in all groups. The authors
suggested that weight loss diet and probiotics yogurt had effects on gene expression in PBMCs among
overweight and obese individuals [36–38].
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An 8-week, randomized, double-blind, placebo- and compliance-controlled parallel study in
overweight and obese subjects was conducted to evaluated the effects of one strain of E. faecium and
two strains of S. thermophilus [39]. The patients were randomly divided into five groups: (1) a yogurt
fermented with two strains of S. thermophilus and two strains of L. acidophilus; (2) a placebo yogurt
fermented with delta-acid-lactone; (3) a yogurt fermented with two strains of S. thermophilus and
one strain of L. rhamnosus; (4) a yogurt fermented with one strain of E. faecium and two strains of
S. thermophiles; and finally (5) two placebo pills daily [39]. After adjustment for small changes in body
weight, low-density lipoprotein cholesterol (LDL-C) decreased and fibrinogen increased significantly
after 8 weeks in the group that received the yogurt fermented with one strain of E. faecium and two
strains of S. thermophilus compared to the group consuming chemically fermented yogurt and the
placebo pill group. Additionally, after 8 weeks, the systolic BP was significantly more reduced in group
1 and the group that received the yogurt fermented with one strain of E. faecium and two strains of
S. thermophilus than in group 3 [39].
The administration of capsules with bifidobacteria, lactobacilli, and S. thermophilus was conducted
in overweight subjects. The probiotic mixture had a significant improvement in their lipid profiles,
reducing total cholesterol (TC), triacylglycerols (TAG), and LDL-C levels and increasing high-density
lipoprotein cholesterol (HDL-C) levels. The probiotic mixture improved insulin sensitivity and
decreased C-reactive protein (CRP) [40].
On the other hand, a total of 58 obese, postmenopausal women were randomized into a
single-blinded, parallel-group intervention of 6-week duration, with a daily ingestion of L. paracasei
F19, flaxseed mucilage or placebo. The intake of L. paracasei F19 did not modulate any metabolic
markers (homeostasis model assessment of insulin resistance (HOMA-IR), Matsuda index, CRP, and
lipid profile) compared with the placebo [41]. Moreover, the intake of L. acidophilus La5 and B. animalis
subsp. lactis Bb12 not affected the HOMA-IR, BP, heart rate or serum lipid concentrations in overweight
adults [42,43].
2.1.2. Synbiotics
The impact of L. rhamnosus CGMCC1.3724 with oligo-fructose and inulin supplementation was
investigated on weight loss and maintenance in obese men and women during 24 weeks [12].
The mean weight loss in women in the L. rhamnosus group was significantly higher than in
women in the placebo group after the first 12 weeks, whereas it was similar in men in the two groups.
The L. rhamnosus-induced weight loss in women was associated not only with significant reductions in
fat mass and circulating leptin concentrations but also with the relative abundance of bacteria of the
Lachnospiraceae family in the feces; this family belongs to the Firmicutes phylum, a taxonomic group
that has previously been reported to be positively associated with obesity [12].
In obese children, two studies determined the effect of synbiotic supplementation on
cardiometabolic risk factors, anthropometric measurements, serum lipid profile, and oxidative
stress levels. The intake of synbiotics resulted in a significant reduction in the BMI z-score and
waist circumference, as well as in some cardiometabolic risk factors, such as TC, LDL-C and
TAG [36,37], and also changes in anthropometric measurements (% reduction comparing to baseline)
were significantly higher in the children receiving synbiotics. After synbiotic supplementation,
total oxidative stress serum levels significantly decreased [44,45].
In summary, the supplementation of selected probiotics appears to have beneficial effects on
BMI, waist circumference, VFA and hip circumference in overweight or obese people. Moreover,
it has been reported that some probiotic strains modulate the gene expression of specific transcription
factors such as ROR-γt (down-regulated) and FOXP3 (up-regulated) in PBMCs. This was associated
with beneficial effects on the immune system among overweight and obese individuals. However,
no effects were observed at the level of inflammatory biomarkers in the administration of L. paracasei
F19, and L. acidophilus La5 and B. animalis subsp. lactis Bb12. On the other hand, some synbiotics
can reduce BMI in women, decrease fat mass and serum leptin levels and increase the levels of the
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Lachnospiraceae family in the feces. Finally, synbiotic treatment would help to decrease the BMI z-score
and waist circumference in children, as well as TC, LDL-C and TAG serum levels. Table 1 summarizes
the studies of probiotics and synbiotics in obesity.
Table 1. Summary of randomized clinical intervention trials of probiotics and synbiotics in obesity.





adolescents L. salivarius Ls-33 12 wk






with obesity L. salivarius Ls-33, 10






5 ˆ 1010 CFU 12 wk
Reduction in BMI, abdominal





large VFA L. gasseri SBT2055, 10
8 CFU 12 wk
Reduction in BMI, waist,
abdominal VFA and hip
circumference.
Sharafedtinov
et al., 2013 [35]
40 adults
with obesity L. plantarum 1.5 ˆ 10
11 CFU/g 3 wk







L. acidophilus La5, B. lactis
Bb12, and L. casei DN001,
108 CFU/g
8 wk
Changes in gene expression in
PBMCs as well as BMI, fat
percentage and leptin levels.
Agerholm-Larsen
et al., 2000 [39]
70 overweight and
obese subjects
E. faecium and two strains of
S. thermophilus 8 wk
Reduction in body weight,







and S. thermophilus 6 wk
Improvement in lipid profile,







9.4 ˆ 1010 CFU 6 wk No effect.




L. acidophilus La5 and
B. animalis subsp. lactis Bb12 6 wk









6 ˆ 108 CFU, and inulin 36 wk
Weight loss and reduction in






L. casei, L. rhamnosus,
S. thermophilus, B. breve,
L. acidophilus, B. longum,
L. bulgaricus, and FOS
8 wk Decrease in BMI z-score andwaist circumference.
Ipar et al.,
2015 [45] 77 obese children
L. acidophilus, L. rhamnosus,
B. bifidum, B. longum,
E. faecium, and FOS
4 wk
Changes in anthropometric
measurements. Decrease in TC,
LDL-C and total oxidative stress
serum levels.
Abbreviations: BMI, body mass index; BP, blood pressure; CFU, colony-forming-unit; CRP, C-reactive
protein; FOS, fructo-oligossacharides; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C,
low-density lipoprotein cholesterol; PBMC, peripheral blood mononuclear cell; PM, postmenopausal; TC,
total cholesterol; VFA, visceral fat area; wk, week.
2.2. Effects of Probiotics and Synbiotics on Insulin Resistance Syndrome
2.2.1. Probiotics
The effects of Lactobacillus casei Shirota were evaluated in patients with IRS for studying the
gut permeability, the presence of endotoxin and neutrophil function, the insulin sensitivity index,
quantitative insulin sensitivity check index, insulin sensitivity by oral glucose tolerance test, HOMA-IR
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and β-cell function. The gut permeability increases, but the endotoxin and neutrophil function
remain unaffected [46]. The only parameter that improved after probiotic administration was insulin
sensitivity index [47]. IRS in postmenopausal women is an important risk factor for cardiovascular
morbidity, especially stroke and coronary heart disease and mortality. The effectiveness of L. plantarum
or placebo was evaluated in postmenopausal women over the course of 90 days. The TC, interleukin
(IL)-6 and γ-glutamyltranspeptidase (γ-GTP) levels were significantly decreased in both groups at the
end of the study, whereas the LDL-C level was significantly lower in the placebo group. Glucose and
homocysteine levels were significantly reduced in the L. plantarum group compared with the placebo
group [48].
2.2.2. Synbiotics
Patients with IRS were supplemented with either synbiotic capsules containing seven strains plus
fructo-oligosaccharide or placebo capsules to evaluate the insulin resistance and lipid profile. Levels of
fasting blood sugar and insulin resistance were improved significantly in the synbiotic group [49].
In summary (Table 2), some probiotic strains have beneficial effects such as decreasing the
cell adhesion molecule-1 levels. Moreover, in postmenopausal women, L. plantarum decreased TC,
IL-6 γ-GTP, glucose and homocysteine levels after 90 days. Finally, synbiotic mixture improved the
insulin resistance and HDL-C and reduced the TAG and TC levels in subjects with IRS.
Table 2. Summary of randomized clinical intervention trials of probiotics and synbiotics in insulin
resistance syndrome.





with IRS L. casei Shirota, 3 ˆ 6.5 ˆ 10



















L. casei, L. rhamnosus, S. thermophilus,
B. breve, L. acidophilus, B. longum,
L. bulgaricus, and FOS
28 wk
The levels of fasting blood
sugar and insulin resistance
improved significantly.
Abbreviations: CFU, colony-forming-unit; FOS, fructo-oligossacharides; IRS, insulin resistance syndrome;
sVCAM-1, soluble vascular cell adhesion molecule-1; wk, week.
2.3. Effects of Probiotics and Synbiotics in Type 2 Diabetes
2.3.1. Probiotics
Hariri et al. (2015) investigated the effect of consuming probiotic soy milk containing L. plantarum
A7 or soy milk alone. Each day, the subjects received probiotic soy milk or regular soy milk to
supplement their usual diet. Probiotic soy milk significantly decreased the levels of promoter
methylation in the proximal and distal MLH1 promoter region compared with the baseline values,
while the plasma concentration of 8-hydroxy-20-deoxyguanosine decreased significantly compared
with the subjects receiving soy milk. Additionally, a significant increase in superoxide dismutase
activity was observed in the probiotic soy milk group compared with the baseline value. However,
there were no significant changes from baseline in the promoter methylation of MSH2 within either
group. Therefore, L. plantarum A7-inoculated soy milk can have antioxidative properties and decrease
the risk of mismatched base pairs in DNA among patients with T2D [50].
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L. acidophilus La-5 and B. animalis subsp. lactis BB-12 administration was evaluated on T2D patients.
There was a significant difference between groups concerning mean changes in the HbA1c, TC and
LDL-C levels [51]. In addition, an increase in HDL-C levels and a decrease in the LDL-C/HDL-C ratio
in the intervention group [52].
Previous studies using the same strains [53,54] were carried out in T2D patients. The authors
reported significantly decreased fasting blood glucose, TC, LDL-C and hemoglobin A1c levels as well as
increased erythrocyte superoxide dismutase and glutathione peroxidase activity and total antioxidant
status compared with the control group. They concluded that probiotic yogurt is a promising tool
for diabetes management, and it may be a functional food that can exert antidiabetic and antioxidant
properties [53,54].
In a double-blind, randomized study, males with T2D, impaired or normal glucose tolerance
were enrolled and placed on a 4-week treatment course with either L. acidophilus NCFM or a placebo
to investigate the effects of oral supplementation with the probiotic on insulin sensitivity and the
inflammatory response [55]. After the treatment, the probiotic strain was detected in 75% of the fecal
samples. Insulin sensitivity was preserved only among volunteers in the L. acidophilus NCFM group.
Finally, baseline inflammatory markers and the systemic inflammatory response were unaffected by
the L. acidophilus NCFM supplementation [55].
2.3.2. Synbiotics
The synbiotic supplementation was used to determine the effects on metabolic profiles, CRP and
oxidative stress in T2D patients. The multispecies probiotic supplement consisted of 7 viable and
freeze-dried strains and fructo-oligosaccharides. A significant increase in HOMA-IR in both groups
was detected. However, the increase in the placebo group was significantly higher than that in the
probiotic group. The mean changes in serum CRP were significantly lower in the experimental group.
Additionally, probiotic supplementation led to a significant increase in the plasma total glutathione
levels compared to the placebo [56].
A clinical trials were performed in T2D patients to examined the effects of synbiotic bread
contained L. sporogenes and inulin. Consumption of the synbiotic bread resulted in a significant
reduction in the serum insulin levels, HOMA-IR, and homeostatic model assessment-β-cell function,
serum lipid profile (TAG, TC/HDL-C) and a significant increase in the serum HDL-C levels compared
to the control bread [57,58].
Finally, a synbiotic shake containing L. acidophilus, B. bifidum and fructo-oligosaccharides was
investigated on glycemic and cholesterol levels in elderly people with T2D. The TC, TAG, HDL-C
and blood sugar levels were evaluated. The synbiotic group did not experience any reduction in total
cholesterol and TAG levels, but had a significant increase in HDL-C and a significant reduction in
fasting glycemia [59].
In summary (Table 3), some of the effects of probiotics in subjects with T2D included a lower
fasting blood glucose level, improved insulin sensitivity and an increased antioxidant status. Some
synbiotics increased the total glutathione levels, HDL-C and reduced the fasting glycemia levels
and CRP. Moreover, an improved serum lipid profile was observed in patients with T2D after the
consumption of synbiotics.
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Table 3. Summary of randomized clinical intervention trials of probiotics and synbiotics in type
2 diabetes.





with T2D L. plantarum A7 8 wk
Decreased methylation





L. acidophilus La-5 and B. animalis






et al., 2014 [52]
44 patients
with T2D
L. acidophilus La-5 and B. animalis
subsp. lactis BB-12 8 wk






with T2D L. acidophilus La5 and B. lactis Bb12 6 wk





with T2D L. acidophilus La5 and B. lactis Bb12 6 wk TC and LDL-C improvement.
Andreasen et al.,
2010 [55] 45 males with T2D L. acidophilus NCFM 4 wk No effect.
Synbiotics




L. acidophilus, L. casei, L. rhamnosus,
L. bulgaricus, B. breve, B. longum,
S. thermophilus, 109 CFU,
and 100 mg FOS
8 wk
Increased HOMA-IR and TGL
plasma level; reduced CRP
in serum.
Tajadadi-Ebrahimi
et al., 2014 [57]
81 patients
with T2D
L. sporogenes, 1ˆ108 CFU and
0.07 g inulin per 1 g
8 wk








L. sporogenes, 1ˆ108 CFU and
0.07 g inulin per 1 g
8 wk
Decrease in serum lipid profile
(TAG, TC/HDL-C) and a
significant increase in serum
HDL-C levels.




L. acidophilus 108 CFU/mL,
B. bifidum 108 CFU/mL and
2 g oligofructose
2 wk Increased HDL-C and reducedfasting glycemia.
Abbreviations: 8-OHDG; 8-hydroxy-21-deoxyguanosine; CFU, colony-forming-unit; CRP, C-reactive protein;
FOS, fructo-oligossacharides; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model
assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; SOD, superoxide dismutase, T2D,
type 2 diabetes; TAG, triacylglycerols; TC, total cholesterol; TGL, total glutathione levels; wk, week.
2.4. Effects of Probiotics and Synbiotics in Non-Alcoholic Fatty Liver Disease
2.4.1. Probiotics
The effects of L. bulgaris and S. thermophilus were measured on different parameters of liver
function and cardiovascular risk factors. This treatment revealed a decrease in alanine amino
transferase (ALT), aspartate amino transferase (ASP) and γ-GTP levels as indicators of improving liver
function [60].
On the other hand, in obese children with NAFLD treated with L. rhamnosus strain GG, presented
a significant decrease in the titer of anti-peptidoglycan-polysaccharide antibodies, which are suitable as
an indirect indicator of SIBO. Moreover, in this randomized clinical trial, a restoration of liver function
was also observed in the probiotic group through a decrease in ALT [61].
A double-blind, randomized, controlled clinical trial was conducted using a probiotic yogurt with
L. acidophilus La5 and B. lactis Bb12 for 8 weeks on patients with NAFLD. L. acidophilus La5 and B. lactis
Bb12 consumption resulted in a reduction in the serum levels of ALT, ASP, TC, and LDL-C compared
with the control group [62].
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In another randomized study, Alisi et al. (2014) found a significant improvement in fatty liver
severity (evaluated by ultrasound) and a significant decrease in the BMI of children with NAFLD
who were treated with bifidobacteria, lactobacilli, and S. thermophilus strains for 4 months. These data
suggest that those strains might reduce liver fat and therefore prevent the progression of NAFLD [63].
Furthermore, Alisi et al. (2014) [63] also evaluated glucagon-like peptide 1 (GLP-1), which is an
incretin secreted by cells from the small intestine and proximal colon. GLP-1 is dependent on the
presence of nutrients in the lumen of the small intestine. Its physiological effects include the activation
of catabolism via an increase in insulin secretion and the suppression of glucagon secretion [63,64].
In this sense, Alisi et al. (2014) [63] showed that the circulating levels of the total and active forms of
GLP-1 were significantly elevated in the patients after 4 months of treatment with synbiotics. Although
there is not yet an adequate amount of data, in humans it has been observed that the use of probiotics
improves the efficacy of lifestyle modifications in obese individuals with NAFLD, may improve
conventional liver function tests, and may decrease markers of lipid peroxidation [60,61,63,65,66] and
NASH [67]. This improvement in liver function could be due to a decrease in SIBO and/or dysbiosis
and consequently a minor metabolic endotoxemia in the host because the restoration of normal gut
microbiota might reduce intestinal permeability.
2.4.2. Synbiotics
The translocation of products derived from bacteria such as lipopolysaccharide (LPS), ethanol
and SCFA leads to their arrival to the liver from the intestinal lumen. Additionally, SCFAs stimulated
the synthesis and storage of hepatic triacylglycerols. This process can saturate the detoxification
mechanisms of the liver, resulting in an accumulation of intrahepatic triacylglycerol (IHTG) content,
thus increasing the fatty liver severity. Recently, a randomized study on the use of a synbiotic that
contains five probiotics (L. plantarum, L. delbrueckii spp. bulgaricus, L. acidophilus, L. rhamnosus, B. bifidum
and inulin) over 6 months in adults with NASH produced a significant decrease in IHTG [67].
On the other hand, it is well known that LPS induces pro-inflammatory cytokines, such as tumor
necrosis factor (TNF)-α, which play a critical role in insulin resistance and hepatic inflammatory
cell recruitment in NAFLD. In fact, the evaluation of supplementation with a synbiotic, which is
a mixture of L. casei, L. rhamnosus, S. thermophilus, B. breve, L. acidophilus, B. longum, L. bulgaricus
and fructo-oligosaccharides, in a study with 52 adults over 28 weeks, demonstrated that synbiotic
supplementation inhibited NF-κB and reduced TNF-α production [65]. These authors indicated
an important limitation in their study, as they did not evaluate the gut microbiota to confirm the
mechanism of action suggested. Furthermore, these results are still controversial because similar
studies did not detect significant modifications in the values of TNF-α following treatment with several
probiotics [60,61] and different synbiotics [63,67]. This could be explained by the large differences in
several variables observed in the different studies, including the intervention period, the probiotic
doses, and the bacterial strains used as well as the study subjects.
In summary (Table 4), some probiotics produced positive effects, mainly by improving liver
function and decreasing SIBO. In the case of some synbiotics, the results showed a reduction in liver
fat and TNF-α production to prevent NAFLD and its progression.
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Table 4. Summary of randomized clinical intervention trials of probiotics and synbiotics in
non-alcoholic fatty liver disease.
Reference Subjects Strain/Dose Time Main Outcome
Probiotics





1.2 ˆ 109 CFU/day 8 wk
Decreased ALT and PG-PS
IgAg antibodies.





L. bulgaris and S. thermophilus,







L. acidophilus La5 and B. breve subsp.
lactis Bb12 8 wk
Reduced serum levels of ALT,
ASP, TC, and LDL-C.





and S. thermophilus 16 wk








L. plantarum, L. delbrueckii spp.
bulgaricus, L. acidophilus,
L. rhamnosus, B. bifidum and inulin
26 wk Decreased IHTG content.





L. casei, L. rhamnosus, S. thermophilus,
B. breve, L. acidophilus, B. longum,
L. bulgaricus, and FOS
30 wk Inhibition of NF-κB andreduction of TNF-α.
Abbreviations: ALT, alanine amino transferase; ASP, aspartate amino transferase; CFU, colony-forming-unit;
FOS, fructo-oligossacharides; γ-GTP, γ-glutamyltranspeptidase; GLP1, glucagon-like peptide 1; IHTG,
intrahepatic triacylglycerol, LDL-C, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver
disease; NF-κB, nuclear factor κB; TC, total cholesterol; TNF-α, tumor necrosis factor α; wk, week.
3. Methodology
A comprehensive search of the relevant literature was performed in electronic databases, including
MEDLINE (PubMed), EMBASE and Cochrane Library. MEDLINE through PubMed was searched for
human clinical trial articles that were published between 2000 and 2016 in English using the MeSH
terms “probiotics” and “synbiotics” combined with “obesity”, “insulin resistance”, “diabetes mellitus,
type 2”, “non-alcoholic fatty liver disease” and “metabolic syndrome X”. Here, we evaluate results
obtained using the following equation search: (“obesity”[All Fields] OR “insulin resistance”[All Fields]
OR “metabolic syndrome X”[All Fields] OR “non-alcoholic fatty liver disease”[All Fields] OR “diabetes
mellitus, Type 2”[All Fields]) AND (“probiotics”[All Fields] OR “synbiotics”[All Fields]) AND Clinical
Trial[ptyp], which yielded 66 articles. Only were included the human clinical studies regarding to
obesity, IRS, T2D and NAFLD participants. A total of 36 articles were selected and revised. Additionally,
we searched the reference lists of the included studies for potential relevant literature.
4. Conclusions
The present review focuses on the clinical effects that support the use of probiotics as a coadjuvant
strategy for the prevention and treatment of obesity, IRS, T2D and NAFLD. The current scientific
evidence regarding to overweight and obese patients that received some probiotics and synbiotics
shows a significant reduction in the abdominal adiposity and BMI; and also, probiotic supplementation
produced an improvement in the metabolism of carbohydrates, as well as a reduction in the metabolic
stress in patients with T2D and IRS. Moreover, an improved serum lipid profile was observed in
patients with T2D after the consumption of synbiotics. The effects of probiotics in patients with
NAFLD were primarily an improvement in the liver function and metabolic parameters. Some clinical
results reported beneficial effects using both probiotic and synbiotic supplementation. However, in this
review, we discussed some studies that did not show any significant effect of probiotic administration
on these chronic diseases. These contradictory effects in the reported studies might be related to
Int. J. Mol. Sci. 2016, 17, 928 11 of 15
inappropriate design such as diversity, the use of several strains, and the small number of individuals
receiving some interventions.
Undeniably, further studies to evaluate the best dose-response effect of probiotics and synbiotics
are needed, including following up with patients after the probiotic intervention to evaluate the
persistence of their potential beneficial effects in obesity, IRS, T2D, and NAFLD.
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